Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 29, 2014

PacificGMP Increases Production Capacity

PacificGMP doubles its GMP production capacity with the addition of a second System 1000 Bioreactor platform.

PacificGMP, a CMO, has doubled its GMP production capacity with the addition of a second System 1000 Bioreactor platform from GE Healthcare. This second System 1000, with a 500 L working volume, increases PacificGMP’s large scale GMP production capacity to 1000 L for fed and fed-batch production. In addition, it provides an additional 15,000 L of production capacity when run in perfusion mode. The addition provides PacificGMP a total perfusion capacity of 30,000 L.

Expansion of its operational capacity will allow PacificGMP to increase its large scale clinical manufacturing projects for its research clients, customers, and partners.

Source: PacificGMP


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.